Influence of an aliphatic linker between DOTA and synthetic ZHER2:342 Affibody molecule on targeting properties of the 111In-labeled conjugate

Nuclear Medicine and Biology

Volumn 38, Issue 5, 2011, Pages 697-706

  Tolmachev, Vladimir ^a   Feldwisch, Joachim ^a,b   Lindborg, Malin ^b   Baastrup, Barbro ^b   Sandström, Mattias ^c   Orlova, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Affibody molecule; Aminohexanoic acid; DOTA; Indium 111; Linker; Targeting

Indexed keywords

ABY 002; ABY 003; AMINOCAPROIC ACID; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID AMINOCAPROIC ACID BENZYLOXYCARBONYL HER2-342 CONJUGATE IN 111; INDIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BENZYLOXYCARBONYL HER2-342 CONJUGATE IN 111; INDIUM 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TUMOR LEVEL; FEMALE; IN VITRO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PEPTIDE SYNTHESIS; PROTEIN EXPRESSION; RADIOACTIVITY;

6-AMINOCAPROIC ACID; AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MICE; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PEPTIDES; RECOMBINANT FUSION PROTEINS;

EID: 79959632470     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.11.013     Document Type: Article

References (43)

1. Klapper L.N., Glathe S., Vaisman N., Hynes N.E., Andrews G.C., Sela M., et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 1999, 96:4995-5000.
2. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516.
3. Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozacov C., Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93:552-556.
4. Gårdmark T., Wester K., De la Torre M., Carlsson J., Malmström P.U. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005, 95:982-986.
5. Knosel T., Petersen S., Schwabe H., Schluns K., Stein U., Schlag P.M., et al. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch 2002, 440:187-194.
6. Hernes E., Fossa S.D., Berner A., Otnes B., Nesland J.M. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004, 90:449-454.
7. Bartlett J.M., Brawley D., Grigor K., Munro A.F., Dunne B., Edwards J., Type I. receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 2005, 205:522-529.
8. Verri E., Guglielmini P., Puntoni M., Perdelli L., Papadia A., Lorenzi P., et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005, 68:154-161.
9. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
10. Herbst R.S., Davies A.M., Natale R.B., Dang T.P., Schiller J.H., Garland L.L., et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007, 13:6175-6181.
11. Milenic D.E., Garmestani K., Brady E.D., Albert P.S., Ma D., Abdulla A., et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004, 10:7834-7841.
12. Persson M., Gedda L., Lundqvist H., Tolmachev V., Nordgren H., Malmström P.U., et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res 2007, 67:326-331.
13. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007, 67:2773-2782.
14. Mandler R., Wu C., Sausville E.A., Roettinger A.J., Newman D.J., Ho D.K., et al. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst 2000, 92:1573-1581.
15. Spector N., Xia W., El-Hariry I., Yarden Y., Bacus S. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res 2007, 9:205.
16. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
17. Molina R., Barak V., van Dalen A., Duffy M.J., Einarsson R., Gion M., et al. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 2005, 26:281-293.
18. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Cur Pharm Des 2008, 14:2999-3011.
19. Dijkers E.C., de Vries E.G., Kosterink J.G., Brouwers A.H., Lub-de Hooge M.N. Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy. Curr Pharm Des 2008, 14:3348-3362.
20. Nygren P.A. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008, 275:2668-2676.
21. Arora P., Oas T.G., Myers J.K. Fast and faster: a designed variant of the B-domain of protein A folds in 3 microsec. Protein Sci 2004, 13:847-853.
22. Orlova A., Feldwisch J., Abrahmsén L., Tolmachev V. Affibody molecules for molecular imaging and therapy of cancer. Cancer Biother Radiopharm 2007, 22:573-584.
23. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Hoiden-Guthenberg I., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
24. Ahlgren S., Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 2010, 11:581-589.
25. Engfeldt T., Orlova A., Tran T., Bruskin A., Widström C., Karlström A.E., et al. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007, 34:722-733.
26. Orlova A., Tolmachev V., Pehrson R., Lindborg M., Tran T., Sandström M., et al. Synthetic Affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007, 67:2178-2186.
27. Tolmachev V., Velikyan V., Sandström M., Orlova A. HER2-binding Affibody molecule labeled with 68Ga for PET imaging. Direct in vivo comparison with 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010, 37:1356-1367.
28. Baum R.P., Prasad V., Müller D., Schuchardt C., Orlova A., Wennborg A., et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules. J Nucl Med 2010, 51:892-897.
29. Breeman W.A.P., Hofland L.J., de Jong M., Bernard B.F., Srinivasan A., Kwekkeboom D.J., et al. Evaluation of radiolabeled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 1999, 81:658-665.
30. Garcia-Garayoa E., Schweinsberg C., Maes V., Ruegg D., Blanc A., Blauenstein P., et al. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing peptide receptor-positive tumors. Q J Nucl Med Mol Imaging 2007, 51:42-50.
31. García Garayoa E., Schweinsberg C., Maes V., Brans L., Bläuenstein P., Tourwé D.A., et al. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. Bioconjug Chem 2008, 19:2409-2416.
32. Hoffman T.J., Gali H., Smith C.J., Sieckman G.L., Hayes D.L., Owen N.K., et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003, 44:823-831.
33. Zhang H., Chen J., Waldherr C., Hinni K., Waser B., Reubi J.C., et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004, 64:6707-6715.
34. Smith C.J., Gali H., Sieckman G.L., Higginbotham C., Volkert W.A., Hoffman T.J. Radiochemical investigations of 99mTc-N3S-X-BBN[7-14]NH2: an in vitro/in vivo structure-activity relationship study where X=0, 3, 5, 8, and 11-carbon tethering moieties. Bioconjug Chem 2003, 14:93-102.
35. Tolmachev V., Nilsson F.Y., Widström C., Andersson K., Rosik D., Gedda L., et al. 111In-benzyl-DTPA-ZHER2:342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006, 47:846-853.
36. Persson M., Tolmachev V., Andersson K., Gedda L., Sandström M., Carlsson J. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005, 32:1457-1462.
37. Lundberg E., Höidén-Guthenberg I., Larsson B., Uhlén M., Gräslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 2007, 319:53-63.
38. Wållberg H., Orlova A. Slow internalization of anti-HER2 synthetic Affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 2008, 23:435-442.
39. Kenanova V., Wu A.M. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 2006, 3:53-70.
40. Schmidt M.M., Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009, 8:2861-2871.
41. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007, 18:295-304.
42. Breeman W.A., Kwekkeboom D.J., de Blois E., de Jong M., Visser T.J., Krenning E.P. Radiolabelled regulatory peptides for imaging and therapy. Anticancer Agents Med Chem 2007, 7:345-357.
43. Tolmachev V., Orlova A. Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. Curr Med Chem 2010, 17:2636-2655.